AMPLIA THERAPEUTICS LIMITED (ATX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ATX

ATX - AMPLIA THERAPEUTICS LIMITED

FNArena Sector : NONE
Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.03
Index:

0

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.079

19 Nov
2026

-0.002

OPEN

$0.08

-2.47%

HIGH

$0.08

602,036

LOW

$0.08

TARGET
$0.42 431.6% upside
FNARENA'S MARKET CONSENSUS FORECASTS
ATX: 1
Title FY25
Actual
FY26
Actual
FY27
Forecast
FY28
Forecast
EPS (cps) xxx - 1.6 - 2.3 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

$ 

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-1.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx7.7
Net Operating Cash Flow xxxxxxxxxxxxxxx-8.7 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-25.48 %
Return on Invested Capital xxxxxxxxxxxxxxx-25.37 %
Return on Assets xxxxxxxxxxxxxxx-23.94 %
Return on Equity xxxxxxxxxxxxxxx-25.48 %
Return on Total Capital xxxxxxxxxxxxxxx-43.32 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-8.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx28 M
Price To Book Value xxxxxxxxxxxxxxx3.05

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx13 M
Research & Development xxxxxxxxxxxxxxx9 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

04/11/2026

1

Speculative Buy

$0.42

431.65%

Bell Potter highlights growing evidence supporting the combination of Amplia Therapeutics' FAK inhibitor, narmafotinib, with RAS inhibitors to improve cancer treatment outcomes.

FAK stands for Focal Adhesion Kinase, an enzyme involved in cell growth, survival, movement and signalling, while RAS refers to a family of proteins that regulate cell growth and division.

The broker points to encouraging preclinical studies and clinical data suggesting the combination could improve treatment responses and delay disease progression.

Amplia owns one of only three FAK inhibitors in clinical development globally, compared with more than 60 RAS inhibitors in development, the analysts highlight.

A collaboration with Eli Lilly to trial narmafotinib alongside its KRAS inhibitor in lung cancer is expected to provide early efficacy data in 2028.

Bell Potter sees substantial commercial potential, particularly given Amplia's market capitalisation below $50m, but clinical validation remains necessary. Unchanged Speculative Buy rating and 42c target.

FORECAST
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -2.30 cents.
Bell Potter forecasts a full year FY28 dividend of 0.00 cents and EPS of minus -0.70 cents.

EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

ATX STOCK CHART